20/20 Biolabs, Inc. Common Stock (AIDX) - Total Liabilities
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) has total liabilities worth $3.13 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AIDX cash flow metrics to assess how effectively this company generates cash.
20/20 Biolabs, Inc. Common Stock - Total Liabilities Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check AIDX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
20/20 Biolabs, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of 20/20 Biolabs, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Voltaic Strategic Resources Ltd
AU:VSR
|
Australia | AU$147.40K |
|
Equus Total Return Closed Fund
NYSE:EQS
|
USA | $4.90 Million |
|
Linius Technologies Ltd
AU:LNU
|
Australia | AU$3.90 Million |
|
4DS Memory Ltd
AU:4DS
|
Australia | AU$1.42 Million |
|
Climeon AB (publ)
ST:CLIME-B
|
Sweden | Skr32.87 Million |
|
Rudrabhishek Enterprises Limited
NSE:REPL
|
India | Rs671.63 Million |
|
ZICOM Group Ltd
AU:ZGL
|
Australia | AU$92.26 Million |
|
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
|
Turkey | TL1.22 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down 20/20 Biolabs, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of 20/20 Biolabs, Inc. Common Stock.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 28.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 20/20 Biolabs, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual total liabilities of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.08 Million | -0.07% |
| 2023-12-31 | $2.08 Million | -26.77% |
| 2022-12-31 | $2.84 Million | -16.02% |
| 2021-12-31 | $3.38 Million | +162.58% |
| 2020-12-31 | $1.29 Million | +31.91% |
| 2019-12-31 | $976.56K | +19.01% |
| 2018-12-31 | $820.54K | -15.05% |
| 2017-12-31 | $965.94K | +71.89% |
| 2016-12-31 | $561.95K | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more